References:
1. Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S,
McMahon CM. Global burden of ototoxic hearing loss associated with
platinum-based cancer treatment: A systematic review and meta-analysis.
Cancer Epidemiol 2022;79.
2. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al.
Comprehensive audiometric analysis of hearing impairment and tinnitus
after cisplatin-based chemotherapy in survivors of adult-onset cancer. J
Clin Oncol 2016;34(23):2712-2720.
3. Kirkim G, Olgun Y, Aktas S, Kiray M, Kolatan E, Altun Z, et al. Is
there a gender-related susceptibility for cisplatin ototoxicity? Eur
Arch Oto-Rhino-Laryngol 2015;272(10):2755-2763.
4. El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC,
Jr., et al. Clinical and genome-wide analysis of cisplatininduced
tinnitus implicates novel ototoxic mechanisms. Clin Cancer Res
2019;25(13):4104-4116.
5. Coling DE, Ding D, Young R, Lis M, Stofko E, Blumenthal KM, et al.
Proteomic analysis of cisplatin-induced cochlear damage: Methods and
early changes in protein expression. Hear Res 2007;226(1-2):140-156.
6. Bielefeld EC, Gonzalez A, DeBacker JR. Changing the time intervals
between cisplatin cycles alter its ototoxic side effect. Hear Res
2021;404.
7. Chan SL, Ng LS, Goh X, Siow CH, Goh HL, Goh BC, et al. Time course
and clinical characterization of cisplatin-induced ototoxicity after
treatment for nasopharyngeal carcinoma in a South East Asian population.
Head Neck 2018;40(7):1425-1433.
8. Miaskowski C, Paul SM, Mastick J, Abrams G, Topp K, Smoot B, et al.
Associations Between Perceived Stress and Chemotherapy-Induced
Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors. J Pain
Symptom Manage 2018;56(1):88-97.
9. Gentilin E, Simoni E, Candito M, Cazzador D, Astolfi L.
Cisplatin-Induced Ototoxicity: Updates on Molecular Targets. Trends Mol
Med 2019;25(12):1123-1132.
10. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, et al. Cisplatin-induced
ototoxicity: Updates on molecular mechanisms and otoprotective
strategies. Eur J Pharm Biopharm 2021;163:60-71.
11. Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK,
McLachlin KM, et al. Cisplatin is retained in the cochlea indefinitely
following chemotherapy. Nat Commun 2017;8(1).
12. Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a
review of prevailing ototoxicity criteria. Eur Arch Oto-Rhino-Laryngol
2017;274(3):1187-1196.
13. Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM,
et al. Predicting Hearing Loss after Radiotherapy and Cisplatin
Chemotherapy in Patients with Head and Neck Cancer. JAMA Otolaryngol
Head Neck Surg 2020;146(2):106-112.
14. Ardeshirrouhanifard S, Fossa SD, Huddart R, Monahan PO, Fung C, Song
Y, et al. Ototoxicity after Cisplatin-Based Chemotherapy: Factors
Associated with Discrepancies between Patient-Reported Outcomes and
Audiometric Assessments. Ear Hear 2022;43(3):794-807.
15. Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, et
al. Prevention of cisplatin-induced ototoxicity in children and
adolescents with cancer: a clinical practice guideline. Lancet Child
Adolesc Health 2020;4(2):141-150.
16. Desilets A, Adam J-, Res DS. Management of cisplatin-associated
toxicities in bladder cancer patients. Curr Opin Support Palliat Care
2020;14(3):286-292.
17. Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH, et
al. Impact of chemotherapy-induced neurotoxicities on adult cancer
survivors’ symptom burden and quality of life. J Cancer Survivorship
2018;12(2):234-245.
18. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
19. Higgins JPT, Savović J, Page MJ, et al. Chapter 8: Assessing risk of
bias in a randomized trial. In: Cochrane Handbook for systematic reviews
of interventions version 6.2. Cochrane,
2021. www.training.cochrane.org/handbook
20. Wells GASB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P
(2016) The Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. https
://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
21. Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of
narrative synthesis in systematic reviews: a product from the ESRC
methods programme, 2006.
22. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES,
Yanovich S, et al. Randomized placebo-controlled multicenter evaluation
of diethyldithiocarbamate for chemoprotection against cisplatin-induced
toxicities. J Clin Oncol 1995;13(2):490-496.
23. Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang L, Raschko JW, et al.
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced
electrolyte wasting, ototoxicity, and epidermal growth factor excretion:
A randomized, placebo-controlled, double-blind trial. J Clin Oncol
1995;13(5):1231-1237.
24.Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al.
Amifostine pretreatment for protection against cyclophosphamide-induced
and cisplatin-induced toxicities: Results of a randomized control trial
in patients with advanced ovarian cancer. J Clin Oncol
1996;14(7):2101-2112.
25.Planting AST, Catimel G, De Mulder PHM, De Graeff A, Höppener F,
Verweij J, et al. Randomized study of a short course of weekly cisplatin
with or without amifostine in advanced head and neck cancer. Ann Oncol
1999;10(6):693-700.
26. Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, et
al. High-dose cisplatin with amifostine: Ototoxicity and
pharmacokinetics. Laryngoscope 2004;114(9 I):1660-1667.
27. Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT. Ototoxic
effects of supradose cisplatin with sodium thiosulfate neutralization in
patients with head and neck cancer. ARCH OTOLARYNGOL HEAD NECK SURG
1997;123(9):978-981.
28. Ishikawa E, Sugimoto H, Hatano M, Nakanishi Y, Tsuji A, Endo K, et
al. Protective effects of sodium thiosulfate for cisplatin-mediated
ototoxicity in patients with head and neck cancer. Acta Oto-Laryngol
2015;135(9):919-924.
29. Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D,
Rosing H, et al. Transtympanic Sodium Thiosulfate for Prevention of
Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. Otol
Neurotol 2021;42(5):678-685.
30.Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA,
et al. Ototoxicity in a randomized phase III trial of intra-arterial
compared with intravenous cisplatin chemoradiation in patients with
locally advanced head and neck cancer. J Clin Oncol
2007;25(24):3759-3765.
31.Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I,
et al. A randomized controlled trial to test the efficacy of
trans-tympanic injections of a sodium thiosulfate gel to prevent
cisplatin-induced ototoxicity in patients with head and neck cancer. J
Otolaryngol Head Neck Surg 2019;48(1).
32. Yildirim M, Inançli HM, Samanci B, Oktay MF, Enöz M, Topçu I.
Preventing cisplatin induced ototoxicity by N-acetylcysteine and
salicylate. Kulak Burun Bogaz Ihtis Derg 2010;20(4):173-183.
33.Riga MG, Chelis L, Kakolyris S, Papadopoulos S, Stathakidou S,
Chamalidou E, et al. Transtympanic injections of N-acetylcysteine for
the prevention of cisplatin-induced ototoxicity: A feasible method with
promising efficacy. Am J Clin Oncol Cancer Clin Trials 2013;36(1):1-6.
34. Yoo J, Hamilton SJ, Angel D, Fung K, Franklin J, Parnes LS, et al.
Cisplatin otoprotection using transtympanic L-N-acetylcysteine: A pilot
randomized study in head and neck cancer patients. Laryngoscope
2014;124(3):E87-E94.
35. Marshak T, Steiner M, Kaminer M, Levy L, Shupak A. Prevention of
cisplatin-induced hearing loss by intratympanic dexamethasone: A
randomized controlled study. Otolaryngol Head Neck Surg
2014;150(6):983-990.
36.Moreno I, Belinchon A. Evaluating the Efficacy of Intratympanic
Dexamethasone in Protecting Against Irreversible Hearing Loss in
Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled
Phase IIIB Clinical Trial. Ear Hear 2022;43(2):676-684.
37. Nasr W, Abdelhady M, Abd Elbary M, Nada E. Treatment of
cisplatin-induced ototoxicity by intra-tympanic corticosteroid
injection. Indian J Otol 2018;24(1):33-37.
38. Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, et
al. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase
II double-blind, randomised controlled trial to establish if aspirin
reduces cisplatin induced hearing-loss. Eur J Cancer 2017;87:75-83.
39. Delarestaghi MM, Mohebbi S, Basi A, Rahbar N, Karbasi Z, Karbasi H.
The Protective Effect of Sertraline in Preventing Cisplatin-induced
Ototoxicity in Solid Organ Chemotherapy. Int Tinnitus J
2018;22(2):175-180.
40. Fernandez KA, Allen P, Campbell M, Page B, Townes T, Li C-, et al.
Atorvastatin is associated with reduced cisplatin induced hearing loss.
J Clin Invest 2021;131(1).
41.Weijl NI, Elsendoorn TJ, Lentjes EGWM, Hopman GD, Wipkink-Bakker A,
Zwinderman AH, et al. Supplementation with antioxidant micronutrients
and chemotherapy-induced toxicity in cancer patients treated with
cisplatin-based chemotherapy: A randomised, double-blind,
placebo-controlled study. Eur J Cancer 2004;40(11):1713-1723.
42.Villani V, Zucchella C, Cristalli G, Galiè E, Bianco F, Giannarelli
D, et al. Vitamin E neuroprotection against cisplatin ototoxicity:
Preliminary results from a randomized, placebo-controlled trial. Head
Neck 2016;38:E2118-E2121.
43.Scasso F, Sprio AE, Canobbio L, Scanarotti C, Manini G, Berta GN, et
al. Dietary supplementation of coenzyme Q10 plus multivitamins to hamper
the ROS mediated cisplatin ototoxicity in humans: A pilot study. Heliyon
2017;3(2).
44.Campbell KC, Rehemtulla A, Sunkara P, Hamstra D, Buhnerkempe M, Ross
B. Oral D-methionine protects against cisplatin-induced hearing loss in
humans: phase 2 randomized clinical trial in India. Int J Audiol
2022;61(8):621-631.
45. Mukherjea D, Dhukhwa A, Sapra A, Bhandari P, Woolford K, Franke J,
et al. Strategies to reduce the risk of platinum containing
antineoplastic drug-induced ototoxicity. Expert Opin Drug Metab Toxicol
2020;16(10):965-982.
46. Duval M, Daniel SJ. Meta-analysis of the efficacy of amifostine in
the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg
2012;41(5):309-315.
47. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, et al. Cisplatin-induced
ototoxicity: Updates on molecular mechanisms and otoprotective
strategies. Eur J Pharm Biopharm 2021;163:60-71.
48. Freyer DR, Frazier AL, Sung L. Sodium thiosulfate and
cisplatin-induced hearing loss. New Engl J Med 2018;379(12):1180-1181.
49. Chen C-, Huang C-, Lin H-H, Wang M-, Chang C-, Cheng Y-. Association
of Sodium Thiosulfate with Risk of Ototoxic Effects from Platinum-Based
Chemotherapy: A Systematic Review and Meta-analysis. JAMA Network Open
2021.
50. Faber J, Fonseca LM. How sample size influences research outcomes.
Dental Press J Orthod 2014;19:27–9.
51. Chauhan RS, Saxena RK, Varshey S. The role of ultrahigh-frequency
audiometry in the early detection of systemic drug-induced hearing loss.
Ear Nose Throat J 2011;90(5).
52. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al.
Comprehensive audiometric analysis of hearing impairment and tinnitus
after cisplatin-based chemotherapy in survivors of adult-onset cancer. J
Clin Oncol 2016;34(23):2712-2720.
53. El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC,
Jr., et al. Clinical and genome-wide analysis of cisplatin induced
tinnitus implicates novel ototoxic mechanisms. Clin Cancer Res
2019;25(13):4104-4116.
54.Clinicaltrials.gov.Efficacy of Sodium Thiosulfate and Mannitol in
Reducing Ototoxicity in Adult Patients Receiving Cisplatin
Chemotherapy[Internet]. 2022 [updated 2022 November 7; cited 2023
January 1]. [1 screen]. ClinicalTrials.gov Identifier: NCT05129748
Available from: https://clinicaltrials.gov/ct2/show/NCT05129748
55. Clinicaltrials.gov.Evaluation of the Effect of Rosuvastatin on
Cisplatin-induced Nephrotoxicity and Ototoxicity[Internet]. 2022
[updated 2021 July 28; cited 2023 January 1]. [1 screen].
ClinicalTrials.gov Identifier: NCT04817904 Available from:
https://clinicaltrials.gov/ct2/show/NCT04817904
56. Clinicaltrials.gov.Intratympanic N-Acetylcysteine for Prevention of
Cisplatin-induced Ototoxicity.[Internet]. 2022 [updated 2022
October 25; cited 2023 January 1]. [1 screen]. ClinicalTrials.gov
Identifier: NCT04291209 Available from:
https://clinicaltrials.gov/ct2/show/NCT04291209
57. Clinicaltrials.gov.Intratympanic Administration of N-acetylcysteine
for Protection of Cisplatin-induced Ototoxicity[Internet]. 2022
[updated 2022 August 15; cited 2023 January 1]. [1 screen].
ClinicalTrials.gov Identifier: NCT04226456 Available from:
https://clinicaltrials.gov/ct2/show/NCT04226456